Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke
, 2, 2, 2, 2, 3, 4, 2, 2
Abstract
Introduction: Despite considerable progress in knowledge, ischaemic stroke is still a disease that causes serious clinical problems. A role in its pathogenesis can be attributed to i.a. adipose tissue hormones. The aim of this paper is to assess the blood levels of selected adipocytokines in patients during the acute phase of ischaemic stroke as compared to healthy persons, and an attempt to indicate a correlation between their blood concentrations and the level of stroke severity and its outcomes.
Material and methods: The study included 46 patients with fresh ischaemic stroke (27 females, 19 males, average age 67.6 years). All patients had a CT scan of the head, their neurological condition was assessed using a stroke severity scale, and their blood levels of resistin, chemerin, and visfatin were tested. The control group consisted of 32 patients (16 females, 16 males, average age 64.1 years) who had never suffered cerebrovascular diseases.
Results: Elevated levels of both resistin and chemerin were found in the group of patients with ischaemic stroke (9.17 ± 2.95 ng/mL vs. 6.55 ± 2.01 ng/mL for resistin and 265.0 ± 59.3 ng/mL vs. 191.0 ± 43.6 ng/mL for chemerin). It was also found that the blood concentration of chemerin was higher in females than in males with stroke. However, no difference was found in visfatin blood concentration between the group with ischaemic stroke and the control group (1.65 ± 1.09 ng/mL vs. 1.5 ± 1.39 ng/mL).
Conclusions: Higher resistin and chemerin blood concentrations significantly increase the risk of ischaemic stroke. The level of stroke severity at the moment of its occurrence and during its course do not depend on the concentrations of adipocytokines under analysis.
Keywords: ischaemic strokeadipocytokinesresistinchemerinvisfatin
References
- WHO: The Atlas of Heart Disease and Stroke: Global burden of stroke. http://www.who.int/cardiovascular_ diseases/resources/atlas/en.
- Grabowska-Fudala B, Jaracz K, Górna K. [Stroke incidence, case fatality and mortality — current trends and future prognosis]. Przegl Epidemiol. 2010; 64(3): 439–442.
- Członkowska A, Ryglewicz D. Epidemiologia udarów mózgu w Polsce. Neurol Neurochir Pol. 1999; 32(Suppl 6): 99–103.
- Powers WJ, Rabinstein AA, Ackerson T, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3): e46–e4e110.
- Alper BS, Malone-Moses M, McLellan JS, et al. Thrombolysis in acute ischaemic stroke: time for a rethink? BMJ. 2015; 350: h1075.
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89(6): 2548–2556.
- Meier U. Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin. Clinical Chemistry. 2004; 50(9): 1511–1525.
- Machura E, Szczepańska M, Świętochowska E, et al. Evaluation of adipokines in children with cystic fibrosis. Endokrynol Pol. 2018; 69(2): 128–134.
- Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005; 111(7): 932–939.
- Osawa H, Doi Y, Makino H, et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2009; 8: 60.
- Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008; 93(7): 2647–2653.
- Olszanecka-Glinianowicz M, Kocełak P, Orlik B, et al. Nowe adipokiny — korzystne czy niekorzystne w aspekcie patogenezy insulinooporności? Endokrynol Otył Zab Przem Mat. 2009; 5: 236–242.
- Kaur J, Mattu H, Chatha K, et al. Chemerin in human cardiovascular disease. Vascul Pharmacol. 2018; 110: 1–6.
- Cybulska B. Wisfatyna — co dotychczas wiadomo o jej roli w fizjologii i patologii? Komentarz redakcyjny. Kardiol Pol. 2011; 69(8): 808–809.
- Prugger C, Luc G, Haas B, et al. PRIME Study Group. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol. 2012; 71(4): 478–486.
- Denes J, Zsippai A, Kovacs L, et al. Comparison of adipose tissue derived genes in endogenous Cushing's syndrome versus diet-induced obesity. Endokrynol Pol. 2019; 70(2): 131–134.
- Dyaczyński M, Scanes CG, Koziec H, et al. Endocrine implications of obesity and bariatric surgery. Endokrynol Pol. 2018; 69(5): 574–597.
- Qian H, Gingerich R, Mistry J. Differences in the expression pattern of resistin protein in the serum and adipose tissueof ob/ob mice. Diabetes. 2003; 52: A86–A87.
- Way JM, Görgün CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2001; 276(28): 25651–25653.
- Cao H, Hegele RA. Single nucleotide polymorphisms of the resistin (RSTN) gene. J Hum Genet. 2001; 46(9): 553–555.
- Bogdański P, Musialik K, Szulińska M, et al. Ocena stężenia rezystyny u pacjentów z nadciśnieniem tętniczym i zespołem metabolicznym. Endokrynol Otył Zab Przem Mat. 2006; 2(4): 116–121.
- Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008; 93(7): 2647–2653.
- Tsukahara T, Nakashima E, Watarai A, et al. Polymorphism in resistin promoter region at –420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009; 84(2): 179–186.
- Perovic E, Mrdjen A, Harapin M, et al. Diagnostic and prognostic role of resistin and copeptin in acute ischemic stroke. Top Stroke Rehabil. 2017; 24(8): 614–618.
- Jurin I, Paić F, Bulimbašić S, et al. Association between Circulatory and Plaque Resistin Levels with Carotid Plaque Instability and Ischemic Stroke Events. Heart Surg Forum. 2018; 21(6): E448–E463.
- Li Ya, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One. 2014; 9(12): e113915.
- Xiaotao Li, Xiaoxia Z, Yue X, et al. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis. 2012; 23(6): 412–416.
- Kaur J, Mattu HS, Chatha K, et al. Chemerin in human cardiovascular disease. Vascul Pharmacol. 2018; 110: 1–6.
- Zhao D, Bi G, Feng J, et al. Association of Serum Chemerin Levels with Acute Ischemic Stroke and Carotid Artery Atherosclerosis in a Chinese Population. Med Sci Monit. 2015; 21: 3121–3128.
- Gasbarrino K, Mantzoros C, Gorgui J, et al. Circulating Chemerin Is Associated With Carotid Plaque Instability, Whereas Resistin Is Related to Cerebrovascular Symptomatology. Arterioscler Thromb Vasc Biol. 2016; 36(8): 1670–1678.
- Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307(5708): 426–430.
- Mazaherioun M, Hosseinzadeh-Attar MJ, Janani L, et al. Elevated serum visfatin levels in patients with acute myocardial infarction. Arch Iran Med. 2012; 15(11): 688–692.
- Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism. 2007; 56(8): 1131–1134.
- Ilhan N, Susam S, Canpolat O, et al. The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke. Br J Neurosurg. 2019; 33(5): 504–507.
- Kadoglou NPE, Fotiadis G, Lambadiari V, et al. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis. Peptides. 2014; 57: 12–16.
- Pitoulias MG, Skoura L, Pitoulias AG, et al. The role of Visfatin in atherosclerotic peripheral arterial obstructive disease. Cytokine. 2017; 91: 140–144.
- Marousi SG, Theodorou GL, Karakantza M, et al. Acute post-stroke adiponectin in relation to stroke severity, progression and 6 month functional outcome. Neurol Res. 2010; 32(8): 841–844.
- Bienek R, Marek B, Kajdaniuk D, et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol. 2012; 63(5): 338–345.
- Efstathiou SP, Tsiakou AG, Tsioulos DI, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta. 2007; 378(1-2): 78–85.
